A Multi-Center, Randomized, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VGR-R01 in Subjects with Bietti Crystalline Dystrophy
Latest Information Update: 27 Nov 2024
Price :
$35 *
At a glance
- Drugs VGR-R01 (Primary)
- Indications Bietti crystalline dystrophy
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Vitalgen BioPharma
- 27 Nov 2024 New trial record